Aspreva says FDA fast-tracks CellCept lupus drug
LOS ANGELES, June 6 (Reuters) - Aspreva Pharmaceuticals Corp. ASPV.O on Wednesday said the U.S. Food and Drug Administration has granted "fast-track" status to its experimental drug CellCept for the treatment of lupus nephritis.
The FDA's Fast Track designation is designed to speed up the application and review process for products that have the potential to address a serious or life-threatening condition. There has been no new approved treatment for lupus in the United States in over 30 years, the company said.
Aspreva is evaluating CellCept for the treatment of lupus nephritis in a global phase III study. Lupus nephritis is a complication of systemic lupus erythematosusis involving severe inflammation of the kidney and may progress rapidly to renal failure.
© Thomson Reuters 2008 All rights reserved
Help us advance this story. Provide relevant links or share your insights using our comment box. Please be considerate and help us by reporting any abuse you find. Reuters will delete comments that don't meet community standards.
Have a correction to this article? Email the editors
Sphere
Austria Killings
Betancourt keeps options open